IPP Bureau
Diabeloop bags FDA nod for DBLG2, opens US market for automated insulin delivery
By IPP Bureau - January 12, 2026
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies
By IPP Bureau - January 12, 2026
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
AbbVie to acquire West Pharmaceutical’s Arizona device manufacturing facility
By IPP Bureau - January 12, 2026
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility
By IPP Bureau - January 12, 2026
The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants
Novartis to open Florida radioligand facility
By IPP Bureau - January 12, 2026
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Johnson & Johnson strikes deal With Trump admn to cut drug costs, expand manufacturing
By IPP Bureau - January 11, 2026
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
By IPP Bureau - January 11, 2026
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera
By IPP Bureau - January 11, 2026
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy
By IPP Bureau - January 11, 2026
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Pulmocide halts Phase 3 trial of Opelconazole in severe lung infection
By IPP Bureau - January 11, 2026
The decision follows an interim analysis conducted when roughly half of the patients had completed their Day 84 visit
Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
By IPP Bureau - January 11, 2026
DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases
NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
By IPP Bureau - January 11, 2026
The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
By IPP Bureau - January 11, 2026
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
Merck initiates phase 3 trial of calderasib with Keytruda QLEX for NSCLC
By IPP Bureau - January 11, 2026
KRAS G12C-mutant advanced or metastatic nonsquamous non-small cell lung cancer
Prokaryotics and Basilea team up to tackle deadly fungal infections
By IPP Bureau - January 11, 2026
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
